Protagonist Therapeutics, Inc. Forecast, price target & analysts
Protagonist Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Protagonist Therapeutics, Inc. Classifications & Recommendation:
Protagonist Therapeutics, Inc. Price Target
| Target Price | $58.73 |
| Price | $36.34 |
| Potential |
61.61%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Protagonist Therapeutics, Inc. 2026 .
The average Protagonist Therapeutics, Inc. target price is $58.73.
This is
61.61%
register free of charge
$68.00
87.12%
register free of charge
$38.00
4.57%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Protagonist Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Protagonist Therapeutics, Inc. stock has an average upside potential 2026 of
61.61%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 434.43 | 87.00 |
| 624.05% | 79.97% | |
| EBITDA Margin | 58.88% | -172.64% |
| 139.11% | 393.19% | |
| Net Margin | 59.43% | -97.94% |
| 142.03% | 264.79% |
11 Analysts have issued a sales forecast Protagonist Therapeutics, Inc. 2025 . The average Protagonist Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Protagonist Therapeutics, Inc. EBITDA forecast 2025. The average Protagonist Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Protagonist Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Protagonist Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 4.23 | -1.40 |
| 404.32% | 133.10% | |
| P/E | negative | |
| EV/Sales | 20.95 |
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast for earnings per share. The average Protagonist Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Protagonist Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Protagonist Therapeutics, Inc....
Current Protagonist Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs | Locked ➜ Locked | Locked | Feb 24 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 24 2025 |
| JMP Securities | Locked ➜ Locked | Locked | Feb 07 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 07 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Feb 04 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 10 2024 |
| BMO Capital | Locked ➜ Locked | Locked | Dec 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Feb 04 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
BMO Capital: Locked ➜ Locked
|
Dec 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
